
## Marco Zappa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5557405/publications.pdf Version: 2024-02-01



Μαρίο Ζάρα

#	Article	IF	CITATIONS
1	Long-Term Follow-up of the Italian Flexible Sigmoidoscopy Screening Trial. Annals of Internal Medicine, 2022, 175, 36-45.	3.9	25
2	Prognostic selection and long-term survival analysis to assess overdiagnosis risk in lung cancer screening randomized trials. Journal of Medical Screening, 2021, 28, 39-47.	2.3	6
3	A Retrospective Cohort Study of Young Women Spontaneously Choosing to Be Vaccinated against HPV: Outcomes from Their First Cervical Cancer Screening Test. Viruses, 2021, 13, 486.	3.3	3
4	Moderate-severe coronary calcification predicts long-term cardiovascular death in CT lung cancer screening: The ITALUNG trial. European Journal of Radiology, 2021, 145, 110040.	2.6	11
5	Synthetic indicator of the impact of colorectal cancer screening programmes on incidence rates. Gut, 2020, 69, 311-316.	12.1	6
6	Faecal haemoglobin concentration among subjects with negative FIT results is associated with the detection rate of neoplasia at subsequent rounds: a prospective study in the context of population based screening programmes in Italy. Gut, 2020, 69, 523-530.	12.1	33
7	Smoking Cessation in the ITALUNG Lung Cancer Screening: What Does "Teachable Moment―Mean?. Nicotine and Tobacco Research, 2020, 22, 1484-1491.	2.6	38
8	A standardized use of intraoperative anastomotic testing in colorectal surgery in the new millennium: is technology taking over? A systematic review and network meta-analysis. Techniques in Coloproctology, 2019, 23, 625-631.	1.8	31
9	Decreased cardiovascular mortality in the ITALUNG lung cancer screening trial: Analysis of underlying factors. Lung Cancer, 2019, 138, 72-78.	2.0	15
10	Associations between cervical, breast and colorectal cancer screening uptake, chronic diseases and health-related behaviours: Data from the Italian PASSI nationwide surveillance. Preventive Medicine, 2019, 120, 60-70.	3.4	17
11	Towards evidence-based follow-up intervals for breast cancer survivors: Estimates of the preclinical detectable phase of contralateral second breast cancer. Breast, 2019, 45, 70-74.	2.2	0
12	A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. European Urology, 2019, 76, 43-51.	1.9	359
13	Gastric cancer after gastric bypass with fundectomy: The possibility for early diagnosis. International Journal of Surgery Case Reports, 2019, 55, 156-159.	0.6	1
14	Impact of screening programme using the faecal immunochemical test on stage of colorectal cancer: Results from the IMPATTO study. International Journal of Cancer, 2019, 145, 110-121.	5.1	25
15	Patients' experience of screening CT colonography with reduced and full bowel preparation in a randomised trial. European Radiology, 2019, 29, 2457-2464.	4.5	15
16	Laparoscopic Gastric Bypass with Fundectomy and Gastric Remnant Exploration (LRYGBfse): Results at 5-Year Follow-up. Obesity Surgery, 2018, 28, 2626-2633.	2.1	11
17	Does low-dose aspirin use for cardiovascular disease prevention reduce colorectal cancer deaths? A comparison of two cohorts in the Florence district, Italy. European Journal of Cancer Prevention, 2018, 27, 134-139.	1.3	8
18	Invitation coverage and participation in Italian cervical, breast and colorectal cancer screening programmes. Journal of Medical Screening, 2018, 25, 17-23.	2.3	16

Marco Zappa

#	Article	IF	CITATIONS
19	Cost analysis of colorectal cancer screening with CT colonography in Italy. European Journal of Health Economics, 2018, 19, 735-746.	2.8	5
20	The efficacy of prostateâ€ <b>s</b> pecific antigen screening: Impact of key components in the ERSPC and PLCO trials. Cancer, 2018, 124, 1197-1206.	4.1	56
21	Faecal immunochemical test in subjects not attending screening computed tomography colonography and colonoscopy in a randomized trial. European Journal of Cancer Prevention, 2018, 27, 105-109.	1.3	4
22	Geographical and socioeconomic differences in uptake of Pap test and mammography in Italy: results from the National Health Interview Survey. BMJ Open, 2018, 8, e021653.	1.9	25
23	Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy. BMC Infectious Diseases, 2018, 18, 38.	2.9	35
24	Volumetric breast density and risk of advanced cancers after a negative screening episode: a cohort study. Breast Cancer Research, 2018, 20, 95.	5.0	13
25	Assessment of viral methylation levels for high risk HPV types by newly designed consensus primers PCR and pyrosequencing. PLoS ONE, 2018, 13, e0194619.	2.5	7
26	Detection rate and predictive factors of sessile serrated polyps in an organised colorectal cancer screening programme with immunochemical faecal occult blood test: the EQuIPE study (Evaluating) Tj ETQq0 0	0 r <b>gB.Ti</b> /Ov	verlas∢ck 10 Tf
27	Advanced breast cancer rates in the epoch of service screening: The 400,000 women cohort study from Italy. European Journal of Cancer, 2017, 75, 109-116.	2.8	50
28	Vertical Gastric Bypass with Fundectomy: Feasibility and 2-Year Follow-Up in a Series of Morbidly Obese Patients. Obesity Surgery, 2017, 27, 2145-2150.	2.1	8
29	Indicators of inappropriate tumour marker use through the mining of electronic health records. Journal of Evaluation in Clinical Practice, 2017, 23, 895-902.	1.8	5
30	Digital breast tomosynthesis (DBT): recommendations from the Italian College of Breast Radiologists (ICBR) by the Italian Society of Medical Radiology (SIRM) and the Italian Group for Mammography Screening (GISMa). Radiologia Medica, 2017, 122, 723-730.	7.7	18
31	Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial. Thorax, 2017, 72, 825-831.	5.6	221
32	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Annals of Internal Medicine, 2017, 167, 449.	3.9	160
33	Impact of a new sampling buffer on faecal haemoglobin stability in a colorectal cancer screening programme by the faecal immunochemical test. European Journal of Cancer Prevention, 2017, 26, 285-291.	1.3	11
34	Impact of cause of death adjudication on the results of the European prostate cancer screening trial. British Journal of Cancer, 2017, 116, 141-148.	6.4	11
35	Design-corrected variation by centre in mortality reduction in the ERSPC randomised prostate cancer screening trial. Journal of Medical Screening, 2017, 24, 98-103.	2.3	5
36	Prospective Comparison and Quality of Life for Single-Incision and Conventional Laparoscopic Sleeve Gastrectomy in a Series of Morbidly Obese Patients. Obesity Surgery, 2017, 27, 681-687.	2.1	37

#	Article	IF	CITATIONS
37	Cervical cancer screening in women vaccinated against human papillomavirus infection: Recommendations from a consensus conference. Preventive Medicine, 2017, 98, 21-30.	3.4	49
38	Epidemiology-Based Assessment of Tumor Marker Overordering in Breast Cancer: An Algorithm to Examine Different Disease Conditions. International Journal of Biological Markers, 2017, 32, 471-473.	1.8	2
39	Guidance for faecal occult blood testing: quantitative immunochemical method (FIT-HB) in colorectal cancer screening programmes. Epidemiologia E Prevenzione, 2017, 41, 1-31.	1.1	49
40	Subcapsular hepatic haematoma of the right lobe following endoscopic retrograde cholangiopancreatography: Case report and literature review. World Journal of Gastroenterology, 2016, 22, 4411.	3.3	27
41	PD09-04 ESTIMATING THE HARMS AND BENEFITS OF PROSTATE CANCER SCREENING: COMPARING COMMON CLINICAL PRACTICE TO RECOMMENDED GOOD PRACTICE. Journal of Urology, 2016, 195, .	0.4	0
42	Splenic rupture following colonoscopy: Case report and literature review. International Journal of Surgery Case Reports, 2016, 21, 118-120.	0.6	16
43	PD09-01 CORRELATION BETWEEN STAGE SHIFT AND DIFFERENCES IN MORTALITY BETWEEN THE TWO STUDY ARMS OF THE ERSPC Journal of Urology, 2016, 195, .	0.4	0
44	Effectiveness of HPV vaccination in women reaching screening age in Italy. Journal of Clinical Virology, 2016, 84, 74-81.	3.1	11
45	Correlation between stage shift and differences in mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC). BJU International, 2016, 118, 677-680.	2.5	9
46	Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis. Cancer, 2016, 122, 3386-3393.	4.1	23
47	Impact of variations in triage cytology interpretation onÂhuman papillomavirus–based cervical screening andÂimplications for screening algorithms. European Journal of Cancer, 2016, 68, 148-155.	2.8	37
48	Reduced and Full-Preparation CT Colonography, Fecal Immunochemical Test, and Colonoscopy for Population Screening of Colorectal Cancer: A Randomized Trial. Journal of the National Cancer Institute, 2016, 108, djv319.	6.3	70
49	An epidemiology-based model as a tool to monitor the outbreak of inappropriateness in tumor marker requests: a national scale study. Clinical Chemistry and Laboratory Medicine, 2016, 54, 473-82.	2.3	19
50	Appropriateness of endoscopic surveillance recommendations in organised colorectal cancer screening programmes based on the faecal immunochemical test. Gut, 2016, 65, 1822-1828.	12.1	25
51	Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening. Clinical Cancer Research, 2016, 22, 243-249.	7.0	35
52	Quality of colonoscopy in an organised colorectal cancer screening programme with immunochemical faecal occult blood test: the EQuIPE study (Evaluating Quality Indicators of the) Tj ETQq0 0 0 r	gBT2Øverl	oc <b>k</b> 810 Tf 50
53	HPV prevalence and risk of pre-cancer and cancer in regular immigrants in Italy: results from HPV DNA test-based screening pilot programs. Infectious Agents and Cancer, 2015, 10, 14.	2.6	8

<sup>54</sup>Cost-effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data. Journal of<br/>the National Cancer Institute, 2015, 107, 366.6.3120

#	Article	IF	CITATIONS
55	Changes in cervical cancer incidence following the introduction of organized screening in Italy. Preventive Medicine, 2015, 75, 56-63.	3.4	35
56	Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer. European Urology, 2015, 68, 885-890.	1.9	111
57	Impact of Screening Program on Incidence of Colorectal Cancer: A Cohort Study in Italy. American Journal of Gastroenterology, 2015, 110, 1359-1366.	0.4	110
58	Colorectal cancer screening of immigrants to Italy. Figures from the 2013 National Survey. Preventive Medicine, 2015, 81, 132-137.	3.4	16
59	Participation and Risk of High Grade Cytological Lesions Among Immigrants and Italian-Born Women in an Organized Cervical Cancer Screening Program in Central Italy. Journal of Immigrant and Minority Health, 2015, 17, 670-678.	1.6	13
60	The diffusion of screening programmes in Italy, years 2011-2012. Epidemiologia E Prevenzione, 2015, 39, 5-8.	1.1	5
61	Cancer screening uptake: association with individual characteristics, geographic distribution, and time trends in Italy. Epidemiologia E Prevenzione, 2015, 39, 9-18.	1.1	24
62	Mammographic breast cancer screening in Italy: 2011-2012 survey. Epidemiologia E Prevenzione, 2015, 39, 21-9.	1.1	4
63	Extension of organized cervical cancer screening programmes in Italy and their process indicators, 2011-2012 activity. Epidemiologia E Prevenzione, 2015, 39, 61-76.	1.1	10
64	A first survey of HPV-based screening in routine cervical cancer screening in Italy. Epidemiologia E Prevenzione, 2015, 39, 77-83.	1.1	21
65	Screening for colorectal cancer in Italy: 2011-2012 survey. Epidemiologia E Prevenzione, 2015, 39, 93-107.	1.1	17
66	Screening for colorectal cancer in Italy: 2011-2012 survey. Epidemiologia E Prevenzione, 2015, 39, 108-14.	1.1	3
67	Screening for colorectal cancer in Italy: 2011-2012 survey. Epidemiologia E Prevenzione, 2015, 39, 115-25.	1.1	16
68	An epidemiology-based model to estimate the rate of inappropriateness of tumor marker requests. Clinical Chemistry and Laboratory Medicine, 2014, 52, 889-97.	2.3	7
69	Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet, The, 2014, 383, 524-532.	13.7	1,282
70	Breast cancer mortality trends in Italy by region and screening programme, 1980–2008. Journal of Medical Screening, 2014, 21, 189-193.	2.3	3
71	Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet, The, 2014, 384, 2027-2035.	13.7	1,261
72	Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence. Journal of Clinical Virology, 2014, 60, 257-263.	3.1	25

#	Article	IF	CITATIONS
73	The impact of immunochemical faecal occult blood testing on colorectal cancer incidence. Digestive and Liver Disease, 2014, 46, 82-86.	0.9	105
74	A Different Method of Evaluation of the ERSPC Trial Confirms That Prostate-specific Antigen Testing Has a Significant Impact on Prostate Cancer Mortality. European Urology, 2014, 66, 401-403.	1.9	14
75	Screening for colorectal cancer with FOBT, virtual colonoscopy and optical colonoscopy: study protocol for a randomized controlled trial in the Florence district (SAVE study). Trials, 2013, 14, 74.	1.6	27
76	Screening patterns within organized programs and survival of Italian women with invasive cervical cancer. Preventive Medicine, 2013, 57, 220-226.	3.4	37
77	Re: Lead time and down-staging in the survival of cervical cancer cases detected by screening. Preventive Medicine, 2013, 57, 404-405.	3.4	4
78	Computed tomographic colonography in subjects with positive faecal occult blood test refusing optical colonoscopy. Digestive and Liver Disease, 2013, 45, 285-289.	0.9	19
79	Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial. Journal of Medical Screening, 2013, 20, 33-38.	2.3	18
80	Excess all-cause mortality in the evaluation of a screening trial to account for selective participation. Journal of Medical Screening, 2013, 20, 39-45.	2.3	11
81	Decreasing incidence of lateâ€stage breast cancer after the introduction of organized mammography screening in Italy. Cancer, 2013, 119, 2022-2028.	4.1	51
82	hr-HPV testing in the follow-up of women with cytological abnormalities and negative colposcopy. British Journal of Cancer, 2013, 109, 1766-1774.	6.4	14
83	Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial. Journal of Medical Screening, 2013, 20, 33-38.	2.3	8
84	European guidelines for quality assurance in colorectal cancer screening and diagnosis: Overview and introduction to the full Supplement publication. Endoscopy, 2012, 45, 51-59.	1.8	356
85	Overdiagnosis in Mammographic Screening for Breast Cancer in Europe: A Literature Review. Journal of Medical Screening, 2012, 19, 42-56.	2.3	338
86	European guidelines for quality assurance in colorectal cancer screening and diagnosis. – First Edition Faecal occult blood testing. Endoscopy, 2012, 44, SE65-SE87.	1.8	61
87	HPV Testing Is an Efficient Management Choice for Women With Inadequate Liquid-Based Cytology in Cervical Cancer Screening. American Journal of Clinical Pathology, 2012, 138, 65-71.	0.7	11
88	Does an organised screening programme reduce the inequalities in breast cancer survival?. Annals of Oncology, 2012, 23, 319-323.	1.2	31
89	Quality-of-Life Effects of Prostate-Specific Antigen Screening. New England Journal of Medicine, 2012, 367, 595-605.	27.0	364
90	Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths. Annals of Oncology, 2012, 23, 1325-1334.	1.2	90

#	Article	IF	CITATIONS
91	Breast cancer screening: are we seeing the benefit?. BMC Medicine, 2012, 10, 106.	5.5	25
92	Prostate-Cancer Mortality at 11 Years of Follow-up. New England Journal of Medicine, 2012, 366, 981-990.	27.0	1,105
93	Familial risk of colorectal cancer in subjects attending an organised screening programme. Digestive and Liver Disease, 2012, 44, 80-83.	0.9	11
94	Article Commentary: Introduction. Journal of Medical Screening, 2012, 19, 3-4.	2.3	1
95	Towards an Optimal Interval for Prostate Cancer Screening. European Urology, 2012, 61, 171-176.	1.9	27
96	Balancing harms and benefits of service mammography screening programs: a cohort study. Breast Cancer Research, 2012, 14, R9.	5.0	38
97	Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008. International Journal of Public Health, 2012, 57, 45-47.	2.3	2
98	Determinants of health-related quality of life in morbid obese candidates to gastric banding. Eating and Weight Disorders, 2012, 17, e93-100.	2.5	8
99	Once-Only Sigmoidoscopy Screening for Colorectal Cancer: Incidence and Mortality Follow-up of the Italian Randomized Controlled Trial (SCORE). Gastroenterology, 2011, 140, S-15.	1.3	1
100	Effect of population-based screening on breast cancer mortality. Lancet, The, 2011, 378, 1775-1776.	13.7	32
101	What is the best screening strategy to detect advanced colorectal adenomas? Simulation from ongoing Italian screening experiences. Tumori, 2011, 97, 547-550.	1.1	2
102	Does in Situ Melanoma Really come before Invasive Melanoma? Descriptive Epidemiology Questions this Relationship. Tumori, 2011, 97, 257-257.	1.1	2
103	Female Breast Cancer Status According to ER, PR and HER2 Expression: A Population Based Analysis. Pathology and Oncology Research, 2011, 17, 753-758.	1.9	47
104	More on Screening Mammography. New England Journal of Medicine, 2011, 364, 281-286.	27.0	10
105	High sensitivity of five colorectal screening programmes with faecal immunochemical test in the Veneto Region, Italy. Gut, 2011, 60, 944-949.	12.1	58
106	Once-Only Sigmoidoscopy in Colorectal Cancer Screening: Follow-up Findings of the Italian Randomized Controlled Trial–SCORE. Journal of the National Cancer Institute, 2011, 103, 1310-1322.	6.3	539
107	Acceptability and side-effects of colonoscopy and sigmoidoscopy in a screening setting. Journal of Medical Screening, 2011, 18, 128-134.	2.3	73
108	The diffusion of screening programmes in Italy, year 2009. Epidemiologia E Prevenzione, 2011, 35, 3-7.	1,1	8

#	Article	IF	CITATIONS
109	What is the best screening strategy to detect advanced colorectal adenomas? Simulation from ongoing Italian screening experiences. Tumori, 2011, 97, 547-50.	1.1	1
110	Colorectal cancer incidence rates have decreased in central Italy. European Journal of Cancer Prevention, 2010, 19, 424-425.	1.3	13
111	Laparoscopic adjustable gastric banding via pars flaccida versus perigastric positioning: technique, complications, and results in 2,549 patients. Surgical Endoscopy and Other Interventional Techniques, 2010, 24, 1519-1523.	2.4	67
112	CT colonography before colonoscopy in subjects with positive faecal occult blood test. Preliminary experience. Radiologia Medica, 2010, 115, 1267-1278.	7.7	13
113	Human papillomavirus infection and risk factors in a cohort of Tuscan women aged 18-24: results at recruitment. BMC Infectious Diseases, 2010, 10, 157.	2.9	25
114	Risk of Invasive Cervical Cancer and Cervical Intraepithelial Neoplasia Grade Iii in Central Italy by Area of Birth. Journal of Medical Screening, 2010, 17, 87-90.	2.3	7
115	Prostate Cancer Incidence Rates Have Started to Decrease in Central Italy. Journal of Medical Screening, 2010, 17, 50-51.	2.3	10
116	Is human papillomavirus screening preferable to current policies in vaccinated and unvaccinated women? A cost-effectiveness analysis. Journal of Medical Screening, 2010, 17, 181-189.	2.3	20
117	Influence of seasonal variations in ambient temperatures on performance of immunochemical faecal occult blood test for colorectal cancer screening: observational study from the Florence district. Gut, 2010, 59, 1511-1515.	12.1	90
118	PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer. European Journal of Cancer, 2010, 46, 3053-3060.	2.8	18
119	Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncology, The, 2010, 11, 249-257.	10.7	797
120	The thickness of melanomas has decreased in central Italy, but only for thin melanomas, while thick melanomas are as thick as in the past. Melanoma Research, 2010, 20, 422-426.	1.2	45
121	Mammography screening in Italy: 2008 survey. Epidemiologia E Prevenzione, 2010, 34, 9-25.	1.1	6
122	Re: Cervical Intraepithelial Neoplasia Outcomes After Treatment: Long-term Follow-up From the British Columbia Cohort Study. Journal of the National Cancer Institute, 2009, 101, 1429-1430.	6.3	4
123	Mammographic Screening and Breast Cancer: Florentine Data. Archives of Internal Medicine, 2009, 169, 997.	3.8	1
124	Protein Kinase A Regulatory Subunits in Human Adipose Tissue. Diabetes, 2009, 58, 620-626.	0.6	39
125	Prostate Cancer Mortality Reduction by Prostate-Specific Antigen–Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). European Urology, 2009, 56, 584-591.	1.9	180
126	Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening?. British Journal of Cancer, 2009, 100, 259-265.	6.4	82

#	Article	IF	CITATIONS
127	Prevalence and correlates of pulmonary emphysema in smokers and former smokers. A densitometric study of participants in the ITALUNG trial. European Radiology, 2009, 19, 58-66.	4.5	49
128	An estimate of overdiagnosis 15 years after the start of mammographic screening in Florence. European Journal of Cancer, 2009, 45, 3166-3171.	2.8	68
129	Screening and Prostate-Cancer Mortality in a Randomized European Study. New England Journal of Medicine, 2009, 360, 1320-1328.	27.0	3,540
130	PC DETECTION IN MEN WITH INITIAL PSA LEVELS < 3.0 NG/ML. DATA FROM ERSPC 1993- 2007. Journal of Urology, 2009, 181, 646.	0.4	1
131	Do women ⩾50 years of age need as much screening as women <50 years after they have had negative screening results?. British Journal of Cancer, 2008, 99, 239-244.	6.4	9
132	Effectiveness of service screening: a case–control study to assess breast cancer mortality reduction. British Journal of Cancer, 2008, 99, 423-427.	6.4	75
133	Cost evaluation in a colorectal cancer screening programme by faecal occult blood test in the District of Florence. Journal of Medical Screening, 2008, 15, 175-181.	2.3	26
134	Evaluation of service mammography screening impact in Italy. The contribution of hazard analysis. European Journal of Cancer, 2008, 44, 858-865.	2.8	10
135	Increased Expression and Activity of the Transcription Factor FOXO1 in Nonalcoholic Steatohepatitis. Diabetes, 2008, 57, 1355-1362.	0.6	163
136	Re: Cost-Effectiveness of Cervical Cancer Screening With Human Papillomavirus DNA Testing and HPV-16,18 Vaccination. Journal of the National Cancer Institute, 2008, 100, 1654-1654.	6.3	1
137	Results at Recruitment From a Randomized Controlled Trial Comparing Human Papillomavirus Testing Alone With Conventional Cytology as the Primary Cervical Cancer Screening Test. Journal of the National Cancer Institute, 2008, 100, 492-501.	6.3	259
138	Colorectal Cancer Mortality in Two Areas of Tuscany With Different Screening Exposures. Journal of the National Cancer Institute, 2008, 100, 1818-1821.	6.3	29
139	Comparison of the Conventional Cervical Smear and Liquid-Based Cytology. Acta Cytologica, 2008, 52, 568-574.	1.3	12
140	PSA Use and Incidence of Prostate Biopsy in the Tuscany Region: Is Opportunistic Screening Discounting Biopsy in Subjects with PSA Elevation?. Tumori, 2008, 94, 518-522.	1.1	8
141	Screening for colorectal cancer in Italy: 2006 survey. Epidemiologia E Prevenzione, 2008, 32, 55-68.	1.1	16
142	Sensitivity of latex agglutination faecal occult blood test in the Florence District population-based colorectal cancer screening programme. British Journal of Cancer, 2007, 96, 1750-1754.	6.4	29
143	Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 Assay in Detection of High-Risk Human Papillomavirus and Diagnosis of Biopsy-Confirmed High-Grade Cervical Disease. Journal of Clinical Microbiology, 2007, 45, 364-369.	3.9	35
144	Effects of the Beach Chair Position, Positive End-expiratory Pressure, and Pneumoperitoneum on Respiratory Function in Morbidly Obese Patients during Anesthesia and Paralysis. Anesthesiology, 2007, 107, 725-732.	2.5	116

#	Article	lF	CITATIONS
145	The cytological screening turned out effective also for adenocarcinoma: a population-based case–control study in Trento, Italy. European Journal of Cancer Prevention, 2007, 16, 564-567.	1.3	11
146	Comparing Attendance and Detection Rate of Colonoscopy With Sigmoidoscopy and FIT for Colorectal Cancer Screening. Gastroenterology, 2007, 132, 2304-2312.	1.3	241
147	Gastric cancer after positive screening faecal occult blood testing and negative assessment. Digestive and Liver Disease, 2007, 39, 321-326.	0.9	26
148	Breast Cancer Diagnostic Methods: Screen-Detected and Clinical Cases. An Italian Survey of Women's Experiences. Tumori, 2007, 93, 452-460.	1.1	3
149	The impact of new technologies in cervical cancer screening: Results of the recruitment phase of a large randomised controlled trial from a public health perspective. International Journal of Cancer, 2007, 121, 2729-2734.	5.1	10
150	The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC). Prostate, 2007, 67, 439-446.	2.3	27
151	Association of FOBT-assessed faecal Hb content with colonic lesions detected in the Florence screening programme. British Journal of Cancer, 2007, 96, 218-221.	6.4	81
152	The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment. Gynecologic Oncology, 2007, 107, S230-S232.	1.4	17
153	Human Papillomavirus Testing and Liquid-Based Cytology: Results at Recruitment From the New Technologies for Cervical Cancer Randomized Controlled Trial. Journal of the National Cancer Institute, 2006, 98, 765-774.	6.3	275
154	Prostate cancer specific mortality in the Florence screening pilot study cohort 1992–1993. European Journal of Cancer, 2006, 42, 1858-1862.	2.8	8
155	Mortality Among Discharged Psychiatric Patients in Florence, Italy. Psychiatric Services, 2006, 57, 1474-1481.	2.0	30
156	Prevention of Pouch Dilatation after Laparoscopic Adjustable Gastric Banding. Obesity Surgery, 2006, 16, 132-136.	2.1	34
157	An Unusual Complication of Gastric Banding: Recurrent Small Bowel Obstruction Caused by the Connecting Tube. Obesity Surgery, 2006, 16, 939-941.	2.1	40
158	Histologic Study of Tissue Reaction to the Gastric Band: Does it Contribute to the Problem of Band Erosion?. Obesity Surgery, 2006, 16, 1155-1159.	2.1	30
159	History of negative colorectal endoscopy and risk of rectosigmoid neoplasms at screening flexible sigmoidoscopy. International Journal of Colorectal Disease, 2006, 21, 105-113.	2.2	7
160	Risk-Benefit Analysis of X-Ray Exposure Associated with Lung Cancer Screening in the Italung-CT Trial. American Journal of Roentgenology, 2006, 187, 421-429.	2.2	65
161	Prognostic Significance of p53 and Ki-67 Antigen Expression in Surgically Treated Non–Small Cell Lung Cancer. American Journal of Clinical Pathology, 2006, 125, 425-431.	0.7	22
162	"Does Fecal Occult Blood Testing Really Reduce Mortality? A Reanalysis of Systematic Review Data." By Moayyedi P and Achkar E American Journal of Gastroenterology, 2006, 101, 2433-2433.	0.4	3

#	Article	IF	CITATIONS
163	Evaluation of diagnostic accuracy of screening by fecal occult blood testing (FOBT). Comparison of FOB Gold and OC Sensor assays in a consecutive prospective screening series. International Journal of Biological Markers, 2006, 21, 157-161.	1.8	17
164	Different Kinetics of Immunologic Recovery Using Nelfinavir or Lopinavir/Ritonavir-Based Regimens in Children with Perinatal HIV-1 Infection. International Journal of Immunopathology and Pharmacology, 2005, 18, 729-735.	2.1	10
165	Corrections to "Workgroup III: facilitating screening for colorectal cancer: quality assurance and evaluation. UICC International Workshop on Facilitating Screening for Colorectal Cancer, Oslo, Norway (29 and 30 June 2002)― Annals of Oncology, 2005, 16, 993.	1.2	0
166	Re: Efficacy of Breast Cancer Screening in the Community According to Risk Level. Journal of the National Cancer Institute, 2005, 97, 1704-1704.	6.3	2
167	Re: Efficacy of Breast Cancer Screening in the Community According to Risk Level. Journal of the National Cancer Institute, 2005, 97, 1703-1703.	6.3	3
168	Incidence Trends of Adenocarcinoma of the Cervix in 13 European Countries. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2191-2199.	2.5	314
169	Randomized Trial of Different Screening Strategies for Colorectal Cancer: Patient Response and Detection Rates. Journal of the National Cancer Institute, 2005, 97, 347-357.	6.3	178
170	Re: Role of Detection Method in Predicting Breast Cancer Survival: Analysis of Randomized Screening Trials. Journal of the National Cancer Institute, 2005, 97, 1853-1854.	6.3	4
171	Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991–1994). European Journal of Cancer, 2005, 41, 411-415.	2.8	32
172	Early diagnosis, not differential treatment, explains better survival in service screening. European Journal of Cancer, 2005, 41, 2728-2734.	2.8	42
173	Meeting Report: Breast Cancer in the Older Woman. Tumori, 2004, 90, 437-445.	1.1	1
174	Benign Breast Diseases in Breast Cancer Screening Programs in Italy (2000-2001). Tumori, 2004, 90, 547-549.	1.1	4
175	Persistent Human Papilloma Virus Infection as an Indicator of Risk of Recurrence of High-Grade Cervical Intraepithelial Neoplasia Treated by the Loop Electrosurgical Excision Procedure. Tumori, 2004, 90, 225-228.	1.1	20
176	Lower protection of cytological screening for adenocarcinomas and shorter protection for younger women: the results of a case–control study in Florence. British Journal of Cancer, 2004, 90, 1784-1786.	6.4	87
177	Breast density as a determinant of interval cancer at mammographic screening. British Journal of Cancer, 2004, 90, 393-396.	6.4	115
178	Comparing conventional and liquid-based smears from a consecutive series of 297 subjects referred to colposcopy assessment. Cytopathology, 2004, 15, 168-170.	0.7	6
179	Breast cancer mortality trends in two areas of the province of Florence, Italy, where screening programmes started in the 1970s and 1990s. British Journal of Cancer, 2004, 90, 1780-1783.	6.4	22
180	Increasing trends of cervical adenocarcinoma incidence in Central Italy despite Extensive Screening Programme, 1985–2000. Cancer Detection and Prevention, 2004, 28, 461-464.	2.1	34

#	Article	IF	CITATIONS
181	Triage with human papillomavirus testing of women with cytologic abnormalities prompting referral for colposcopy assessment. Cancer, 2004, 105, 2-7.	4.1	36
182	Clinical impact (cost-effectiveness) of qualifying atypical squamous cells of undeterminate significance (ASCUS) in cases favoring a reactive or dysplastic process. Diagnostic Cytopathology, 2003, 29, 4-7.	1.0	3
183	A feasibility study of the use of the AutoPap screening system as a primary screening and location-guided rescreening device. Cancer, 2003, 99, 129-134.	4.1	19
184	Mammography screening in elderly women: efficacy and cost-effectiveness. Critical Reviews in Oncology/Hematology, 2003, 46, 235-239.	4.4	14
185	Comparison of standard and double reading and computer-aided detection (CAD) of interval cancers at prior negative screening mammograms: blind review. British Journal of Cancer, 2003, 89, 1645-1649.	6.4	56
186	Debate on colorectal cancer screening by faecal occult blood. Annals of Oncology, 2003, 14, 342-343.	1.2	1
187	Surveillance for endometrial cancer with transvaginal ultrasonography of breast cancer patients under tamoxifen treatment. British Journal of Cancer, 2003, 88, 1175-1179.	6.4	8
188	Exposure to benzene and risk of leukemia among shoe factory workers. Scandinavian Journal of Work, Environment and Health, 2003, 29, 51-59.	3.4	28
189	Baseline Findings of the Italian Multicenter Randomized Controlled Trial of "Once-Only Sigmoidoscopy"SCORE. Journal of the National Cancer Institute, 2002, 94, 1763-1772.	6.3	206
190	Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood. Journal of Medical Screening, 2002, 9, 99-103.	2.3	57
191	Recurrence after Treatment by Loop Electrosurgical Excision Procedure (LEEP) of High-Grade Cervical Intraepithelial Neoplasia. Tumori, 2002, 88, 478-480.	1.1	17
192	Pre-operative prediction of invasive vs intraductal breast cancer type: multivariate analysis of the accuracy of clinical and imaging findings. Breast, 2002, 11, 151-155.	2.2	0
193	Quantification of the effect of mammographic screening on fatal breast cancers: The Florence Programme 1990–96. British Journal of Cancer, 2002, 87, 65-69.	6.4	69
194	Measuring interval cancers in population-based screening using different assays of fecal occult blood testing: The district of Florence experience. International Journal of Cancer, 2001, 92, 151-154.	5.1	76
195	Incidence of second cancers among women with in situ carcinoma of the breast. Breast, 2001, 10, 438-441.	2.2	4
196	Prostate Cancer: Different Incidence But Not Mortality Trends Within Two Areas of Tuscany, Italy. Journal of the National Cancer Institute, 2001, 93, 876-877.	6.3	17
197	Measuring interval cancers in populationâ€based screening using different assays of fecal occult blood testing: The district of Florence experience. International Journal of Cancer, 2001, 92, 151-154.	5.1	1
198	Detection of False-Negative Pap Smears using the Papnet System. Tumori, 2000, 86, 455-457.	1.1	3

#	Article	IF	CITATIONS
199	Colorectal Cancer Screening by Fecal Occult Blood Testing: Results of a Population-Based Experience. Tumori, 2000, 86, 384-388.	1.1	22
200	Screening for colorectal cancer by faecal occult blood test: comparison of immunochemical tests. Journal of Medical Screening, 2000, 7, 35-37.	2.3	41
201	Has the PSA wave already crashed upon us? Changes in the epidemiology of prostate cancer from 1985 to 1994 in central Italy. Annals of Oncology, 1999, 10, 361-362.	1.2	8
202	Biliointestinal Bypass: Another Surgical Option. Obesity Surgery, 1998, 8, 566-569.	2.1	25
203	Ultrasonographic evaluation of the cervical lymph nodes in preoperative staging of esophageal neoplasms. Abdominal Imaging, 1998, 23, 275-277.	2.0	28
204	Asymmetric N-(3,3-diphenylpropyl)aminoalkyl esters of 4-aryl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acids with antihypertensive activity. European Journal of Medicinal Chemistry, 1998, 33, 399-420.	5.5	18
205	Re: Participation in Colorectal Cancer Screening: a Review. Journal of the National Cancer Institute, 1998, 90, 465-465.	6.3	8
206	Overdiagnosis of prostate carcinoma by screening: An estimate based on the results of the Florence Screening Pilot Study. Annals of Oncology, 1998, 9, 1297-1300.	1.2	79
207	A First Survey of Organized Cervical Cancer Screening Programs in Italy. Tumori, 1998, 84, 624-630.	1.1	11
208	Measurement of the Cost of Screening for Cervical Cancer in the District of Florence, Italy. Tumori, 1998, 84, 631-635.	1.1	11
209	Risk of Endometrial Cancer in Breast Cancer Patients under Long-Term Adjuvant Treatment with Tamoxifen. Tumori, 1998, 84, 21-23.	1.1	14
210	Risk of breast cancer subsequent to histological or clinical diagnosis of fibroadenoma - retrospective longitudinal study of 3938 cases. Annals of Oncology, 1997, 8, 297-300.	1.2	25
211	Colposcopy as a Primary Screening test for Cervical Cancer. Tumori, 1997, 83, 810-813.	1.1	12
212	Effect of faecal occult blood testing on colorectal mortality: Results of a population-based case-control study in the district of Florence, Italy. , 1997, 73, 208-210.		74
213	Immunochemical vs guaiac faecal occult blood tests in a population-based screening programme for colorectal cancer. British Journal of Cancer, 1996, 74, 141-144.	6.4	79
214	The detectability of breast cancer by screening mammography. British Journal of Cancer, 1995, 71, 337-339.	6.4	51
215	Trends in the Prevalence of Cervical Intraepithelial Neoplasia Grade 3 in the District of Florence, Italy. Tumori, 1995, 81, 330-333.	1.1	1
216	Comparing Two Modalities of Screening for Prostate Cancer: Digital Rectal Examination + Transrectal Ultrasonography Vs. Prostate-Specific Antigen. Tumori, 1995, 81, 225-229.	1.1	22

#	Article	IF	CITATIONS
217	A Feasibility Study of Screening for Endometrial Carcinoma in Postmenopausal Women by Ultrasonography. Tumori, 1995, 81, 334-337.	1.1	15
218	Measurement of the Costs in Two Mammographic Screening Programmes in the Province of Florence, Italy. Journal of Medical Screening, 1995, 2, 191-194.	2.3	12
219	Assessment of Lesions Detected at Mammographic Screening: Performance at First or Repeat Screening in the Florence Programme. Journal of Medical Screening, 1994, 1, 188-192.	2.3	13
220	Breast cancer early diagnosis experience in Florence: can a self referral policy achieve the results of service screening?. Journal of Epidemiology and Community Health, 1994, 48, 471-475.	3.7	13
221	Population-based breast cancer survival. Mammographic screening activities in central italy. Cancer, 1994, 74, 3126-3134.	4.1	10
222	Prognostic value of proliferating cell nuclear antigen in lymph node—negative breast cancer patients. Cancer, 1993, 72, 120-125.	4.1	34
223	Occupation and Cancers of the Lung and Bladder: A Case-Control Study in Bombay. International Journal of Epidemiology, 1993, 22, 1205-1206.	1.9	Ο
224	Lung cancer among textile workers in the Prato area of Italy Scandinavian Journal of Work, Environment and Health, 1993, 19, 16-20.	3.4	10
225	Pleural malignant mesothelioma in Tuscany, Italy (1970-1988): II. Identification of occupational exposure to asbestos. American Journal of Industrial Medicine, 1992, 21, 577-585.	2.1	14
226	Further evidence of an excess of risk of pleural malignant mesothelioma in textile workers in Prato (Italy). British Journal of Cancer, 1991, 64, 377-378.	6.4	11
227	Malignant mesothelioma in non-asbestos textile workers in florence. American Journal of Industrial Medicine, 1987, 11, 249-254.	2.1	24
228	An asbestos hazard in the reprocessed textile industry. American Journal of Industrial Medicine, 1987, 11, 255-266.	2.1	33